Mirati Seeks Differentiation, Amgen Invests In Combos To Dominate KRAS G12C Field
Biomarker Data Confirm Amgen Strategy; Mirati’s Drug Works In CNS
Amgen outlined the most frequent co-mutations in treatment-resistant lung and colorectal cancers at ASCO, while Mirati’s adagrasib showed efficacy in active CNS metastases in lung cancer patients.
You may also be interested in...
In this week's podcast version of Five Must-Know Things: paradigm-shifting breast cancer and KRAS inhibitor results at ASCO; BMS’ targeted oncology acquisition; a snapshot of the multiple sclerosis market; and a look at Aduhelm one year later.
The US regulator will review adagrasib on standard timelines, leaving some investors anxious about Mirati’s efforts to rival Amgen’s Lumakras.
Amgen’s KRAS G12C inhibitor in combination with the company’s Vectibix generated a 27% overall response rate, nearly tripling the responses seen with Lumakras monotherapy in colorectal cancer.